First participant in Impaact P1113 study vaccinated
Great excitement reigned at the Worcester SATVI Field Site when the first baby participant in the IMPAACT P 1113 Study was vaccinated with the Aeras-404 candidate TB vaccine.
According to Principal Investigator Dr Michele Tameris,
“IMPAACT P1113/Aeras C-015-404, a collaborative study, is
a multicentre trial of the International Maternal Pediatric
Adolescent AIDS Clinical Trials Group (IMPAACT) and is sponsored
by Aeras in conjunction with the National Institute of Allergy
and Infectious Diseases (NIAID) and the Eunice Kennedy Shriver
National Institute of Child Health and Human Development
(NICHD).”
Participating babies will be between
9 and 14 weeks old and will receive 3 doses of AERAS- 404 with
follow up for about 15 months. Three other sites are part of
this trial - KIDCRU at Stellenbosch University, PHRU in
Johannesburg and Shandukani in Soweto.
Source:
SATVI
